PMID- 22964147
OWN - NLM
STAT- MEDLINE
DCOM- 20121220
LR  - 20181023
IS  - 1007-3418 (Print)
IS  - 1007-3418 (Linking)
VI  - 20
IP  - 4
DP  - 2012 Apr
TI  - [Expression of epidermal fatty acid-binding protein in cross-species 
      hepatocellular carcinoma].
PG  - 270-4
LID - cma.j.issn.1007-3418.2012.04 [pii]
LID - 10.3760/cma.j.issn.1007-3418.2012.04.009 [doi]
AB  - OBJECTIVE: To evaluate the utility of the cross-species screening strategy for 
      investigating key molecule(s) involved in onset and progression of hepatocellular 
      carcinoma (HCC). METHODS: HCC-related molecule data from our previous studies and 
      in the literature were collected to establish a cross-species dataset. Tissue 
      samples of HCC, non-HCC surrounding liver (para-HCC), and normal liver that were 
      collected from humans, tree shrews and rats. The genes reported to have the most 
      differential expression in HCC were verified by analyzing the mRNA and protein 
      levels by reverse transcription-polymerase chain reaction (RT-PCR) and Western 
      blotting, respectively. RESULTS: The cross-species dataset of HCC-related 
      molecules included four genes: epidermal fatty acid-binding protein (E-FABP), 
      liver (L)-FABP, tyrosine a-ketoglutarate transaminase (TKT), and cytokeratin 
      (CK8). In humans, E-FABP mRNA expression was significantly higher (P less than 
      0.05) in HCC (0.87+/-0.14 vs. para-HCC: 0.64+/-0.12 and normal liver: 
      0.67+/-0.07; F=20.910). Similar results were obtained in tree shrew (HCC: 0.87 
      +/- 0.25 vs. para-HCC: 0.73 +/- 0.19 and normal liver: 0.68+/-0.19; F=3.807) and 
      rat (HCC: 0.97+/-0.22 vs. para-HCC: 0.78+/-0.16 and normal liver: 0.80 +/- 0.13; 
      F=4.482). The Western blotting analyses revealed a similar statistically 
      significant trend. CONCLUSION: The cross-species screening strategy for tumor 
      genes may represent a feasible and convenient process of identifying key 
      molecule(s) for human HCC. E-FABP may be a particularly crucial molecule for 
      hepatocarcinogenesis.
FAU - Shi, Jun-lin
AU  - Shi JL
AD  - Department of Experimental Pathology, Tumor Hospital of Guangxi Medical 
      University, Nanning 530021, China.
FAU - Cao, Ji
AU  - Cao J
FAU - Su, Jian-jia
AU  - Su JJ
FAU - Yang, Chun
AU  - Yang C
FAU - Ou, Chao
AU  - Ou C
FAU - Wang, Duo-ping
AU  - Wang DP
FAU - Li, Yuan
AU  - Li Y
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - China
TA  - Zhonghua Gan Zang Bing Za Zhi
JT  - Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of 
      hepatology
JID - 9710009
RN  - 0 (Fatty Acid-Binding Proteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Animals
MH  - Carcinoma, Hepatocellular/*metabolism
MH  - Case-Control Studies
MH  - Epidermis/chemistry
MH  - Fatty Acid-Binding Proteins/*metabolism
MH  - Female
MH  - Humans
MH  - Liver/*metabolism
MH  - Liver Neoplasms/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Rats
MH  - Tupaiidae/metabolism
EDAT- 2012/09/12 06:00
MHDA- 2012/12/21 06:00
CRDT- 2012/09/12 06:00
PHST- 2012/09/12 06:00 [entrez]
PHST- 2012/09/12 06:00 [pubmed]
PHST- 2012/12/21 06:00 [medline]
AID - cma.j.issn.1007-3418.2012.04 [pii]
AID - 10.3760/cma.j.issn.1007-3418.2012.04.009 [doi]
PST - ppublish
SO  - Zhonghua Gan Zang Bing Za Zhi. 2012 Apr;20(4):270-4. doi: 
      10.3760/cma.j.issn.1007-3418.2012.04.009.